[{"id":"e36e7d0b-dea5-4fa8-afc8-fa11a5c8624f","acronym":"ASPIRE","url":"https://clinicaltrials.gov/study/NCT03691493","created_at":"2021-01-18T18:05:38.724Z","updated_at":"2025-02-25T14:07:17.394Z","phase":"Phase 2","brief_title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","source_id_and_acronym":"NCT03691493 - ASPIRE","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/08/2019","start_date":" 02/08/2019","primary_txt":" Primary completion: 10/13/2022","primary_completion_date":" 10/13/2022","study_txt":" Completion: 10/13/2022","study_completion_date":" 10/13/2022","last_update_posted":"2025-02-17"},{"id":"e8ce3ccf-c1c8-4ee0-b8b5-f9d8061d44e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00667121","created_at":"2021-01-18T02:29:16.873Z","updated_at":"2025-02-25T14:39:15.807Z","phase":"","brief_title":"Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline","source_id_and_acronym":"NCT00667121","lead_sponsor":"Mayo Clinic","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 03/16/2011","start_date":" 03/16/2011","primary_txt":" Primary completion: 05/12/2014","primary_completion_date":" 05/12/2014","study_txt":" Completion: 05/27/2014","study_completion_date":" 05/27/2014","last_update_posted":"2025-02-14"},{"id":"db930c87-92ac-41c5-ad78-232d08feae0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00949598","created_at":"2021-01-18T03:41:34.600Z","updated_at":"2025-02-25T14:48:25.058Z","phase":"Phase 3","brief_title":"Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer","source_id_and_acronym":"NCT00949598","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" ER • PCNA","pipe":" | ","alterations":" ER positive","tags":["ER • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 177","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 10/01/2010","study_completion_date":" 10/01/2010","last_update_posted":"2025-02-13"},{"id":"60bbdfcc-c05d-4873-8c66-614ba38bb554","acronym":"TAILORx","url":"https://clinicaltrials.gov/study/NCT00310180","created_at":"2021-01-18T01:04:07.094Z","updated_at":"2025-02-25T16:43:29.841Z","phase":"Phase 3","brief_title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","source_id_and_acronym":"NCT00310180 - TAILORx","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10273","initiation":"Initiation: 04/07/2006","start_date":" 04/07/2006","primary_txt":" Primary completion: 03/02/2018","primary_completion_date":" 03/02/2018","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-02-06"},{"id":"972ad6b2-046a-4952-a809-07b8eb832df8","acronym":"CALGB-40503","url":"https://clinicaltrials.gov/study/NCT00601900","created_at":"2021-01-18T02:13:51.918Z","updated_at":"2025-02-25T16:35:58.371Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer","source_id_and_acronym":"NCT00601900 - CALGB-40503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • letrozole • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Soltamox (tamoxifen citrate) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 394","initiation":"Initiation: 09/24/2008","start_date":" 09/24/2008","primary_txt":" Primary completion: 06/30/2014","primary_completion_date":" 06/30/2014","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2025-02-06"},{"id":"a3c29634-7fe3-458b-95a0-a95c7ed454c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101788","created_at":"2021-01-18T09:42:39.713Z","updated_at":"2025-02-25T16:36:20.602Z","phase":"Phase 2/3","brief_title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02101788","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 02/27/2014","start_date":" 02/27/2014","primary_txt":" Primary completion: 04/04/2019","primary_completion_date":" 04/04/2019","study_txt":" Completion: 10/11/2025","study_completion_date":" 10/11/2025","last_update_posted":"2025-02-06"},{"id":"d32e8658-c9d2-4f04-9c89-06bcade2de1e","acronym":"RxPONDER","url":"https://clinicaltrials.gov/study/NCT01272037","created_at":"2021-01-18T05:08:42.199Z","updated_at":"2025-02-25T16:36:08.722Z","phase":"Phase 3","brief_title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","source_id_and_acronym":"NCT01272037 - RxPONDER","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5018","initiation":"Initiation: 01/15/2011","start_date":" 01/15/2011","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-02-06"},{"id":"9663b458-bf8e-4744-aded-694ba1c51e6a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06348134","created_at":"2024-04-04T16:39:16.597Z","updated_at":"2025-02-25T13:56:14.439Z","phase":"Phase 2","brief_title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","source_id_and_acronym":"NCT06348134","lead_sponsor":"University of Chicago","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 07/01/2034","primary_completion_date":" 07/01/2034","study_txt":" Completion: 07/01/2036","study_completion_date":" 07/01/2036","last_update_posted":"2025-02-05"},{"id":"65c1ec6b-055f-4603-b88a-18648345da78","acronym":"EMPRESS","url":"https://clinicaltrials.gov/study/NCT05659563","created_at":"2022-12-21T15:59:16.652Z","updated_at":"2025-02-25T16:54:37.319Z","phase":"Phase 2","brief_title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] \u0026 Ki67≥10%","source_id_and_acronym":"NCT05659563 - EMPRESS","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • giredestrant (RG6171) • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 07/20/2023","start_date":" 07/20/2023","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-04"},{"id":"55cb45be-28da-426b-95b0-c684a21c9966","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311933","created_at":"2021-01-18T10:56:52.952Z","updated_at":"2025-02-25T16:58:44.113Z","phase":"Phase 2","brief_title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02311933","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • NCOA3","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["ER • NCOA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/28/2015","start_date":" 05/28/2015","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 02/04/2025","study_completion_date":" 02/04/2025","last_update_posted":"2025-02-03"},{"id":"08e2ca85-8428-4328-94c8-5d64e49e90df","acronym":"","url":"https://clinicaltrials.gov/study/NCT00893061","created_at":"2021-01-18T03:25:23.407Z","updated_at":"2024-07-02T16:34:25.786Z","phase":"Phase 3","brief_title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","source_id_and_acronym":"NCT00893061","lead_sponsor":"Centre Oscar Lambret","biomarkers":" ER","pipe":" | ","alterations":" PGR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 04/04/2012","primary_completion_date":" 04/04/2012","study_txt":" Completion: 11/26/2014","study_completion_date":" 11/26/2014","last_update_posted":"2024-06-14"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"4eabc33c-7694-415e-ba33-0280ee409656","acronym":"","url":"https://clinicaltrials.gov/study/NCT04129216","created_at":"2021-01-18T20:10:21.050Z","updated_at":"2024-07-02T16:35:05.639Z","phase":"Phase 2","brief_title":"The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer","source_id_and_acronym":"NCT04129216","lead_sponsor":"Johns Hopkins University","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/20/2019","start_date":" 02/20/2019","primary_txt":" Primary completion: 11/10/2022","primary_completion_date":" 11/10/2022","study_txt":" Completion: 11/10/2022","study_completion_date":" 11/10/2022","last_update_posted":"2024-05-07"},{"id":"e264a041-42a7-43c6-8cea-b309a736c283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101564","created_at":"2021-11-01T11:52:59.476Z","updated_at":"2024-07-02T16:35:06.853Z","phase":"Phase 2","brief_title":"Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT05101564","lead_sponsor":"Stanford University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • Truseltiq (infigratinib) • letrozole • zotatifin (eFT226) • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-30"},{"id":"068bd033-5d5c-40ce-a385-1c9ba82a08d5","acronym":"LAPATAM","url":"https://clinicaltrials.gov/study/NCT00424164","created_at":"2021-01-18T01:29:37.157Z","updated_at":"2024-07-02T16:35:15.573Z","phase":"Phase 1","brief_title":"Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT00424164 - LAPATAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2006","start_date":" 11/01/2006","primary_txt":" Primary completion: 06/01/2009","primary_completion_date":" 06/01/2009","study_txt":" Completion: 05/28/2010","study_completion_date":" 05/28/2010","last_update_posted":"2024-03-08"},{"id":"535f285e-41bf-472a-ac17-cca49b4c0883","acronym":"","url":"https://clinicaltrials.gov/study/NCT05150652","created_at":"2021-12-09T18:00:11.490Z","updated_at":"2024-07-02T16:35:21.691Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer","source_id_and_acronym":"NCT05150652","lead_sponsor":"Veronica Morgan Jones","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2036","study_completion_date":" 10/01/2036","last_update_posted":"2024-01-30"},{"id":"d6b8d28f-cf57-448e-abf6-4ebc22b10127","acronym":"SOFT","url":"https://clinicaltrials.gov/study/NCT00066690","created_at":"2021-01-18T00:09:39.396Z","updated_at":"2024-07-02T16:35:24.866Z","phase":"Phase 3","brief_title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","source_id_and_acronym":"NCT00066690 - SOFT","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • triptorelin • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3066","initiation":"Initiation: 12/17/2003","start_date":" 12/17/2003","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-01"},{"id":"b59747c0-577f-45fd-a561-b2bbf5411fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT01674140","created_at":"2021-01-18T07:14:46.881Z","updated_at":"2024-07-02T16:35:25.687Z","phase":"Phase 3","brief_title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT01674140","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • ER • PGR • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1939","initiation":"Initiation: 09/12/2013","start_date":" 09/12/2013","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-12-20"},{"id":"30b7368a-f8fa-42a9-b19a-c1d96001eccd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00499083","created_at":"2021-01-18T01:47:11.312Z","updated_at":"2024-07-02T16:35:35.156Z","phase":"Phase 2","brief_title":"Paclitaxel, Cyclophosphamide \u0026 Doxorubicin, Autologous Dendritic Cells \u0026 Surgery in Stage II/III Breast Cancer (Women)","source_id_and_acronym":"NCT00499083","lead_sponsor":"University of Nebraska","biomarkers":" HER-2 • CEACAM5 • PTGS2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression","tags":["HER-2 • CEACAM5 • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • CEACAM5 positive • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • tamoxifen • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Soltamox (tamoxifen citrate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 07/01/2009","primary_completion_date":" 07/01/2009","study_txt":" Completion: 01/28/2010","study_completion_date":" 01/28/2010","last_update_posted":"2023-09-29"},{"id":"6e6b0160-cdc4-4b39-8c92-7f7d239fef91","acronym":"PRO30178","url":"https://clinicaltrials.gov/study/NCT03219476","created_at":"2021-01-18T15:53:02.691Z","updated_at":"2024-07-02T16:35:41.730Z","phase":"Phase 2","brief_title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","source_id_and_acronym":"NCT03219476 - PRO30178","lead_sponsor":"Medical College of Wisconsin","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/05/2017","start_date":" 02/05/2017","primary_txt":" Primary completion: 02/04/2020","primary_completion_date":" 02/04/2020","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-07-27"},{"id":"3f9dfbae-9bb6-4bbb-a6af-4f158c6e83e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01124695","created_at":"2021-01-18T04:27:52.240Z","updated_at":"2024-07-02T16:35:44.343Z","phase":"Phase 2","brief_title":"Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer","source_id_and_acronym":"NCT01124695","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" ER","pipe":" | ","alterations":" PGR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 01/07/2011","start_date":" 01/07/2011","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-06-29"},{"id":"9750dd78-0d10-4b93-8fc3-202992150271","acronym":"LALEAST","url":"https://clinicaltrials.gov/study/NCT03917082","created_at":"2021-01-18T19:16:10.132Z","updated_at":"2024-07-02T16:35:45.694Z","phase":"Phase 2","brief_title":"Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer","source_id_and_acronym":"NCT03917082 - LALEAST","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 290","initiation":"Initiation: 09/23/2019","start_date":" 09/23/2019","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2023-06-14"},{"id":"3436b807-cfe6-466a-bed6-261455f869e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04433494","created_at":"2021-01-18T21:20:56.931Z","updated_at":"2024-07-02T16:35:59.476Z","phase":"Phase 1","brief_title":"A Study of TY-302 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04433494","lead_sponsor":"TYK Medicines, Inc","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate) • TY-302"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/07/2020","start_date":" 12/07/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-12-07"},{"id":"0b63362f-4ed6-4b42-aae6-d28bb107156e","acronym":"SOFT-EST","url":"https://clinicaltrials.gov/study/NCT00975676","created_at":"2021-01-18T03:48:15.006Z","updated_at":"2024-07-02T16:36:22.522Z","phase":"","brief_title":"Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02","source_id_and_acronym":"NCT00975676 - SOFT-EST","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • exemestane • triptorelin • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 11/25/2008","start_date":" 11/25/2008","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2021-10-25"}]